Ind-Swift Laboratories Limited Q3 FY26 results deck summary

Results deck of 4 Feb 2026, summarised by AI from the filing.

Completed ₹1,650 cr divestment of API & CRAMS business, making ISLL net debt-free.

Key takeaways

1. Strategic reset Completed ₹1,650 cr divestment of API & CRAMS business, making ISLL net debt-free.
2. Regulatory risk Rising regulatory scrutiny globally (MHRA/TGA/HC), favoring compliant manufacturers.

Original filing on BSE

Ind-Swift Laboratories Limited Q1 FY27 results

As filed: Revenue ₹191 cr (+25% year on year), EBITDA ₹33.4 cr (+300% year on year), PAT ₹24.7 cr (+174% year on year), EBITDA margin 17.5% (+1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹170 cr (+23% year on year), EBITDA ₹20.6 cr, PAT ₹15.1 cr (+22% year on year), EBITDA margin 12.1% (+1,000 bps). Score 48 of 100, In line with trend. Revenue and profit before exceptional items growth were in line with the company's own trend. EBITDA margin rose 1000 bps year on year. Tax rate -26%. Profit fell 23% from last quarter. Share price after the results: +49.0% in 28 days (Nifty 500: +0.6%).
• Q3 FY26: Revenue ₹151 cr (+300% year on year), EBITDA ₹4.2 cr, PAT ₹9.5 cr, EBITDA margin 2.8%. Score 75 of 100, Above trend. Revenue growth was well above the company's own trend. Other income 168% of PBT. Share price after the results: +21.0% in 30 days (Nifty 500: −1.1%).
• Q2 FY26: Revenue ₹153 cr (+300% year on year), EBITDA ₹1.0 cr, PAT ₹8.0 cr, EBITDA margin 0.7% (+1,000 bps). Score 79 of 100, Above trend. Revenue growth was well above the company's own trend. EBITDA margin rose 1000 bps year on year. Other income 180% of PBT. Profit fell 11% from last quarter. Share price after the results: −5.6% in 28 days (Nifty 500: −0.5%).
• Q1 FY26: Revenue ₹153 cr (+300% year on year), EBITDA ₹3.0 cr, PAT ₹9.0 cr (+300% year on year), EBITDA margin 2.0% (+1,000 bps). Score 85 of 100, Above trend. Revenue and profit growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Other income 150% of PBT. Profit fell 96% from last quarter. Share price after the results: +6.2% in 30 days (Nifty 500: +1.9%).
• Q4 FY25: Revenue ₹138 cr (−65% year on year), EBITDA −₹10.0 cr, PAT ₹222 cr, EBITDA margin -7.3% (+217 bps). Score 39 of 100, Below trend. Revenue growth was well below the company's own trend. EBITDA margin rose 217 bps year on year. Tax rate 3%.
• Q3 FY25: Revenue ₹9.0 cr, EBITDA −₹15.0 cr, PAT ₹0.0 cr, EBITDA margin -166.7%. Not scored. Too small to score: quarter revenue ₹9.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.
• Q2 FY25: Revenue ₹12.0 cr, EBITDA −₹12.0 cr, PAT ₹0.0 cr, EBITDA margin -100.0%. Not scored. Too small to score: quarter revenue ₹12.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.

Past price moves after results do not indicate future moves. Not a recommendation.

Ind-Swift Laboratories Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (17 Aug 2026), Results deck (17 Aug 2026)
• Q3 FY26: Results deck (4 Feb 2026)
• Q2 FY26: Results deck (14 Jan 2026)